CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 566 enrolled
Drug / intervention
Fesoterodine +1 moredrug
Likely dose
Fesoterodine 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00928070
NCT00928070Phase 4Completed
CompareCT.gov

A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of Fesoterodine Flexible Dose Regimen In Vulnerable Elderly Patients With Overactive Bladder.

Pfizer·interventional·Posted Jun 25, 2009·Updated Jan 17, 2013

In Brief

A Phase 4 clinical trial evaluating Fesoterodine and Placebo for Overactive Bladder. Completed, enrolled 566 participants across 125 sites.

Detailed Summary

This study is designed to assess the efficacy and safety of a flexible dose regimen of fesoterodine on urgency urinary incontinence (UUI) episodes in vulnerable elderly subjects with overactive bladder (OAB).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOveractive Bladder
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 25, 2009
Enrollment StartSep 1, 2009
Primary CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 17.0 years ago

Interventions

Fesoterodinedrug

Fesoterodine 4 mg and 8 mg

Placebodrug

Placebo sham 4 mg and 8 mg